
    
      This is an open-label (identity of assigned study drug will be known), observational study to
      evaluate the safety and efficacy of abiraterone acetate in male Filipino patients with
      advanced metastatic CRPC who have received prior chemotherapy containing a taxane.
      Approximately 50 patients will be enrolled. Abiraterone acetate will be administered
      according to the approved product insert with a low-dose glucocorticoid (prednisone or
      prednisolone). Patient assessments will be based on the accepted clinical practice in the
      Philippines. Patients will be monitored for 40 weeks.
    
  